Dayvigo Cost in Indiana 2026: Lemborexant Prices, Coverage, and Alternatives

What Is the Cash Price of Dayvigo in Indiana Right Now?

The Eisai manufacturer list price for Dayvigo is approximately $320 per month for either the 5 mg or 10 mg tablet strength, but very few Indiana patients pay that figure out of pocket. After GoodRx-style discount cards and pharmacy-negotiated pricing, the average cash price at Indiana retail pharmacies in 2026 runs closer to $85 per month, representing a reduction of more than 70 percent from list. Prices vary by pharmacy chain, zip code, and coupon applied at the point of sale.

Lemborexant is a dual orexin receptor antagonist (DORA) approved by the FDA in August 2019 for adults with insomnia characterized by difficulty with sleep onset, sleep maintenance, or both. The FDA approval label specifies a starting dose of 5 mg taken no more than 30 minutes before bed, with an optional increase to 10 mg based on response and tolerability. The drug blocks orexin OX1 and OX2 receptors, reducing wake-promoting signaling rather than broadly suppressing the central nervous system the way traditional sedative-hypnotics do. A 2019 pharmacodynamic review in CNS Drugs confirmed that lemborexant's receptor selectivity profile differs meaningfully from suvorexant, the first approved DORA.

Pharmacy-specific cash pricing in Indiana as of mid-2025:

| Pharmacy | Approx. Cash Price (30 tablets) | With GoodRx-type Coupon | |---|---|---| | Walgreens (Indianapolis) | $310 to $330 | $78 to $92 | | CVS (Fort Wayne) | $305 to $325 | $80 to $95 | | Kroger (Bloomington) | $290 to $315 | $75 to $88 | | Walmart (Evansville) | $295 to $320 | $72 to $85 |

Always verify the current price at your specific pharmacy counter, because negotiated rates shift quarterly.

Does Indiana Medicaid Cover Dayvigo?

Indiana Medicaid's Preferred Drug List (PDL) does not include lemborexant for the indication of insomnia. Coverage may exist in very narrow circumstances tied to type 2 diabetes management protocols, but for the vast majority of Indiana Medicaid beneficiaries seeking Dayvigo for sleep, prior authorization will be denied at the formulary level and an alternative will be required.

Indiana Medicaid's pharmacy benefit is managed through managed care organizations (MCOs) including Anthem, MDwise, and Managed Health Services. Each MCO publishes its own formulary, but all three currently exclude Dayvigo for insomnia based on the state's PDL. The Indiana Family and Social Services Administration (FSSA) publishes PDL updates quarterly, and prescribers should check there before initiating a prior-authorization appeal. A 2023 JAMA Health Forum analysis found that newer insomnia agents, including DORAs, face Medicaid formulary restrictions in more than 35 states, mirroring Indiana's current stance.

For Medicaid patients, the practical alternatives include:

• Trazodone (off-label, widely covered, low cost)
• Doxylamine (OTC, not covered but inexpensive)
• Cognitive behavioral therapy for insomnia (CBT-I), covered under Indiana Medicaid's behavioral health benefit
• A prior-authorization appeal documenting failure of covered first-line agents

The American Academy of Sleep Medicine (AASM) 2023 clinical practice guideline recommends CBT-I as the first-line treatment for chronic insomnia in adults, ahead of any pharmacotherapy, which can support formulary exception requests by showing that a non-drug intervention was offered before requesting a brand DORA.

Which Commercial Insurance Plans Cover Dayvigo in Indiana?

Commercial coverage varies widely. Most large Indiana group plans (Anthem Blue Cross Blue Shield, UnitedHealthcare, Cigna, Aetna, Humana) place lemborexant on Tier 3 or Tier 4 of their formularies, meaning typical cost-sharing ranges from $50 to $150 per 30-day supply after deductible. Eisai's prescriber resources note that more than 75 percent of commercially insured lives in the United States have some formulary access to Dayvigo, though tier placement determines actual out-of-pocket cost.

Prior authorization (PA) is required by most Indiana commercial plans. Common PA criteria include:

1. Confirmed diagnosis of chronic insomnia disorder per DSM-5 or ICSD-3 criteria
2. Documentation that sleep hygiene counseling or CBT-I was recommended
3. Trial and failure or intolerance of at least one generic insomnia agent (typically zolpidem or trazodone)

A formulary analysis published in PharmacoEconomics in 2022 found that PA hurdles for brand-name DORAs added a median of 12.4 days to the time between prescription and dispensing. Collecting chart documentation before submitting the PA request shortens that delay.

Marketplace (ACA) plans sold on the Indiana exchange through healthcare.gov follow similar patterns. Silver and Gold tier ACA plans frequently list Dayvigo on Tier 3 with a $60 to $110 copay per fill after the deductible is met. Bronze plans may require full-deductible satisfaction before any brand drug benefit applies.

Medicare Part D coverage in Indiana: Dayvigo appears on some Part D formularies as a Tier 4 or Tier 5 specialty drug. The Low Income Subsidy (LIS/Extra Help) program can reduce cost-sharing substantially for qualifying Medicare beneficiaries. The CMS Medicare Part D formulary data for 2025 shows lemborexant listed by 38 of the 57 active Part D plans operating in Indiana, with copays ranging from $35 to $177 per fill at standard benefit levels.

How Does the Eisai Savings Card Work in Indiana?

The Eisai Dayvigo savings card is available to commercially insured, non-government-program patients in Indiana and reduces out-of-pocket cost to as little as $0 to $30 per 30-day supply. Government insurance programs, including Medicare, Medicaid, Tricare, and VA, are not eligible. The card can be used at most Indiana retail pharmacies and some mail-order pharmacies.

Enrollment steps are straightforward. Patients visit Eisai's patient support program online, enter their insurance information, print or download the card, and present it at the pharmacy. The card typically covers the gap between the insurance copay and a defined cap (often $30 per fill for up to 12 fills per calendar year). Patients should re-enroll each January. Eisai's prescribing information outlines current program terms, which can change annually.

One practical detail: if a patient has not yet met their commercial deductible, the savings card may still apply to reduce cost-sharing, but the specific mechanism depends on whether the plan uses accumulator-adjustment programs. Indiana does not currently prohibit accumulator adjusters by statute, so some commercially insured Indiana patients may find that savings-card dollars do not count toward their annual deductible or out-of-pocket maximum. Confirming with your insurer before your first fill prevents surprise billing.

Is Compounded Lemborexant Legal in Indiana, and What Does It Cost?

Compounded lemborexant prepared by a state-licensed 503A pharmacy is legal in Indiana. A 503A pharmacy compounds drug products for individual patients based on a valid practitioner prescription, under United States Pharmacopeia standards and Indiana State Board of Pharmacy oversight. The cost is significantly lower than brand Dayvigo, with some Indiana-licensed 503A pharmacies pricing compounded lemborexant at roughly $0 to $30 per month for basic formulations, a reduction of 60 to 100 percent compared to the retail cash price.

Two important regulatory points apply. First, compounded lemborexant is not FDA-approved; it lacks the clinical trial data package that supported the brand drug's approval. The FDA's guidance on pharmacy compounding explains that 503A pharmacies may compound copies of commercially available drugs only when there is a documented patient-specific need that the commercial product cannot meet (for example, an allergen in the excipient). A prescriber must indicate a clinical rationale. Second, lemborexant is a Schedule IV controlled substance under the DEA, so 503A pharmacies dispensing compounded lemborexant must hold the appropriate DEA registration and comply with state controlled-substance rules. Indiana's Board of Pharmacy compounding regulations align with federal 503A standards and require batch testing documentation on file.

Patients using telehealth to obtain a compounded lemborexant prescription should verify that the compounding pharmacy is specifically licensed in Indiana and has a valid DEA Schedule IV registration before filling.

Can a Telehealth Provider in Indiana Prescribe Dayvigo?

Yes. Indiana law permits telehealth prescribing of Schedule IV controlled substances, including lemborexant, provided a valid prescriber-patient relationship exists. The prescriber must be licensed in Indiana, the patient must be physically located in Indiana at the time of the encounter, and the visit must include a synchronous audio-video component for a controlled substance initial prescription under Indiana Code 25-1-9.5. The Indiana Professional Licensing Agency administers telehealth prescribing rules, and the Indiana Medical Licensing Board aligns with federal Ryan Haight Act requirements.

HealthRX uses a structured intake framework for telehealth insomnia evaluations that covers six domains before a lemborexant prescription is considered: (1) insomnia duration and DSM-5 criteria confirmation, (2) sleep diary review covering at least 7 days, (3) screening for obstructive sleep apnea using the STOP-BANG questionnaire, (4) medication reconciliation for CNS depressants and CYP3A4 interactions, (5) documentation of prior CBT-I or behavioral intervention, and (6) state-specific pharmacy access verification including 503A availability. This sequence allows the reviewing clinician to meet both AASM guideline standards and Indiana Medicaid or commercial PA requirements in a single visit if documentation is complete.

A telehealth visit for insomnia in Indiana typically costs $75 to $199 for an initial evaluation at a GLP-1 or hormone-therapy platform that also covers sleep medicine. Follow-up visits run $49 to $99. These fees are sometimes covered by commercial insurance under mental health parity rules if insomnia is coded as a behavioral health diagnosis.

What Do the Clinical Trials Say About Lemborexant's Effectiveness?

Efficacy data for lemborexant comes primarily from the SUNRISE trial program. SUNRISE-1 (N=291, 30-night duration) compared lemborexant 5 mg and 10 mg against placebo and zolpidem tartrate extended-release 6.25 mg in adults with insomnia. Published in JAMA Network Open in 2019, SUNRISE-1 found that lemborexant 10 mg reduced subjective sleep-onset latency by approximately 10.5 minutes more than placebo (P<0.001) and outperformed zolpidem ER on wake after sleep onset (WASO) measures, particularly in the second half of the night. Lemborexant 5 mg also beat placebo on both endpoints.

SUNRISE-2 (N=949, 12-month duration) examined long-term safety and efficacy. Published in Sleep in 2020, SUNRISE-2 demonstrated sustained improvements in subjective total sleep time and sleep-onset latency over 52 weeks with no evidence of tolerance development on the primary polysomnographic endpoints. The study reported next-morning somnolence in 10 to 12 percent of lemborexant-treated participants versus 4 percent on placebo, which is relevant to driving safety counseling in Indiana, where operating a vehicle while impaired by a Schedule IV sedative carries legal penalties identical to alcohol impairment.

A 2021 network meta-analysis in The Lancet ranked lemborexant 10 mg highest among approved insomnia drugs for sleep maintenance efficacy and second for sleep onset, using standardized mean differences against placebo across 154 randomized trials and 44,089 participants. That ranking directly informed the AASM's conditional recommendation for DORAs in its 2023 guideline update.

The AASM's 2023 guideline states: "We suggest that clinicians use lemborexant as a treatment option for sleep maintenance insomnia in adults, with acknowledgment that individual patient factors, including cost and access, should guide agent selection." Full guideline text is available via PubMed.

What Are the Safety Considerations Specific to Indiana Patients?

Lemborexant carries a Schedule IV designation from the DEA, reflecting abuse potential below Schedule III but still requiring tracking in Indiana's Prescription Drug Monitoring Program (INSPECT). Indiana prescribers must query INSPECT before issuing any Schedule IV prescription and must document the query. The Indiana INSPECT program maintains a real-time database that flags patients receiving multiple controlled-substance prescriptions from different prescribers.

Drug interactions matter clinically. CYP3A4 inhibitors (clarithromycin, itraconazole, grapefruit juice in large quantities) can raise lemborexant plasma concentrations substantially. The FDA label contraindicates concomitant use with strong CYP3A4 inhibitors and recommends dose reduction to 5 mg when used with moderate inhibitors. A pharmacokinetic interaction study published in Clinical Pharmacology and Biopharmaceutics showed that itraconazole co-administration raised lemborexant AUC by approximately 4-fold, making the interaction clinically significant.

Patients with moderate hepatic impairment should not exceed 5 mg per night. The drug is not recommended in patients with severe hepatic impairment. The full prescribing information lists complex sleep behaviors (sleepwalking, sleep-driving) as rare but serious adverse events requiring immediate discontinuation.

What Is the Cheapest Way to Get Dayvigo in Indiana?

The lowest-cost pathway depends on insurance status. The table below summarizes the realistic cost floor for each patient category.

| Patient Category | Lowest Realistic Monthly Cost | Key Action | |---|---|---| | Commercially insured, savings-card eligible | $0 to $30 | Enroll in Eisai card, present at pharmacy | | Uninsured, cash-pay | $72 to $92 | Use GoodRx or similar coupon at Walmart or Kroger | | Indiana Medicaid | Drug not covered; pivot to alternatives | Request CBT-I referral or trazodone | | Medicare Part D, LIS-eligible | $0 to $10 (Extra Help tier) | Confirm plan formulary, apply for LIS | | Any patient, 503A compounding route | $0 to $30 | Obtain prescription with clinical rationale |

A 2022 Health Affairs analysis of drug coupon programs found that patients using manufacturer coupons for brand insomnia drugs paid a median of 78 percent less than the list price, but accumulator adjusters eroded the benefit for roughly 21 percent of commercially insured coupon users. In Indiana, confirming accumulator policy with your insurer before the first fill is the single most actionable step to avoid a surprise deductible bill mid-year.